These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32712246)

  • 1. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect.
    Marcos-Zambrano LJ; Gómez A; Sánchez-Carrillo C; Bouza E; Muñoz P; Escribano P; Guinea J
    Clin Microbiol Infect; 2020 Nov; 26(11):1589-1592. PubMed ID: 32712246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect.
    Marcos-Zambrano LJ; Gómez A; Sánchez-Carrillo C; Bouza E; Muñoz P; Escribano P; Guinea J
    Clin Microbiol Infect; 2018 Dec; 24(12):1343.e1-1343.e4. PubMed ID: 30025834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.
    Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
    Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
    Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates.
    Marcos-Zambrano LJ; Escribano P; Sánchez-Carrillo C; Bouza E; Guinea J
    Med Mycol; 2016 Oct; 54(7):733-9. PubMed ID: 27161788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APX001A
    Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
    Denis J; Ledoux MP; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):8-14. PubMed ID: 29534853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between EUCAST Broth Microdilution and MIC Strip Test in Defining Isavuconazole In Vitro Susceptibility against
    Calvo M; Scalia G; Palermo CI; Oliveri S; Trovato L
    Antibiotics (Basel); 2023 Jan; 12(2):. PubMed ID: 36830162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of isavuconazole against clinically isolated yeasts from Chile.
    Álvarez Duarte E; Salas V
    Braz J Microbiol; 2020 Dec; 51(4):1801-1805. PubMed ID: 32638272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.
    Howard SJ; Lass-Flörl C; Cuenca-Estrella M; Gomez-Lopez A; Arendrup MC
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5426-31. PubMed ID: 23959309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
    Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro combination therapy with isavuconazole against Candida spp.
    Katragkou A; McCarthy M; Meletiadis J; Hussain K; Moradi PW; Strauss GE; Myint KL; Zaw MH; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ; Petraitis V
    Med Mycol; 2017 Nov; 55(8):859-868. PubMed ID: 28204571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
    Seifert H; Aurbach U; Stefanik D; Cornely O
    Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates.
    Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
    J Fungi (Basel); 2022 Oct; 8(10):. PubMed ID: 36294671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.